Alector Inc., a late-stage clinical biotechnology company, released its first-quarter 2025 financial results, reporting $3.7 million in collaboration revenue, a significant decrease from the $15.9 million reported in the same period of 2024. This decline was primarily attributed to the satisfaction of performance obligations related to the AL002 program and the latozinemab FTD-_C9orf72_ Phase 2 trial in the fourth quarter of 2024. The company reported a net loss of $40.5 million for the quarter ended March 31, 2025, compared to a net loss of $36.1 million during the same period in 2024. Research and development expenses decreased to $33.6 million from $45.2 million in the previous year, mainly due to reductions in the AL002 program and personnel costs. General and administrative expenses slightly increased to $14.7 million from $14.4 million in the first quarter of 2024. In terms of business updates, Alector is on track to report topline data from its INFRONT-3 Phase 3 clinical trial of latozinemab in frontotemporal dementia with a granulin gene mutation by the fourth quarter of 2025. The company also completed enrollment in the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease. Alector's cash position, totaling $354.6 million, is anticipated to support operations into the second half of 2027, allowing the company to continue advancing its portfolio of drug candidates for neurodegenerative diseases.